Literature DB >> 29157387

Non-Small-Cell Lung Cancer PET Imaging Beyond F18 Fluorodeoxyglucose.

Gang Cheng1.   

Abstract

F18 Flurodeoxyglucose (FDG) is a nonspecific PET tracer representing tumor energy metabolism, with common false-positive and false-negative findings in clinical practice. Non-small cell lung cancer is highly heterogeneous histologically, biologically, and molecularly. Novel PET tracers designed to characterize a specific aspect of tumor biology or a pathway-specific molecular target have the potential to provide noninvasive key information in tumor heterogeneity for patient stratification and in the assessment of treatment response. Non-FDG PET tracers, including 68Ga-somatostatin analogs, and some PET tracers targeting tumor proliferation, hypoxia, angiogenesis, and pathway-specific targets are briefly reviewed in this article. Published by Elsevier Inc.

Entities:  

Keywords:  Angiogenesis; Carcinoid; Hypoxia; Lung cancer; PET/CT; Personalized therapy; Proliferation

Mesh:

Substances:

Year:  2017        PMID: 29157387     DOI: 10.1016/j.cpet.2017.09.006

Source DB:  PubMed          Journal:  PET Clin        ISSN: 1556-8598


  3 in total

1.  Alternative and New Radiopharmaceutical Agents for Lung Cancer.

Authors:  Silvi Telo; Letizia Calderoni; Sara Vichi; Federico Zagni; Paolo Castellucci; Stefano Fanti
Journal:  Curr Radiopharm       Date:  2020

Review 2.  Spatial heterogeneity of nanomedicine investigated by multiscale imaging of the drug, the nanoparticle and the tumour environment.

Authors:  Josanne Sophia de Maar; Alexandros Marios Sofias; Tiffany Porta Siegel; Rob J Vreeken; Chrit Moonen; Clemens Bos; Roel Deckers
Journal:  Theranostics       Date:  2020-01-01       Impact factor: 11.556

3.  N-staging in large cell neuroendocrine carcinoma of the lung: diagnostic value of [18F]FDG PET/CT compared to the histopathology reference standard.

Authors:  Hubertus Hautzel; Yazan Alnajdawi; Wolfgang P Fendler; Christoph Rischpler; Kaid Darwiche; Wilfried E Eberhardt; Lale Umutlu; Dirk Theegarten; Martin Stuschke; Martin Schuler; Clemens Aigner; Ken Herrmann; Till Plönes
Journal:  EJNMMI Res       Date:  2021-07-22       Impact factor: 3.138

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.